Text this: A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost

 __   __   _    _    __   __   _    _      _____  
 \ \\/ // | || | ||  \ \\/ // | || | ||   / ___// 
  \   //  | || | ||   \   //  | || | ||   \___ \\ 
  / . \\  | \\_/ ||   / . \\  | \\_/ ||   /    // 
 /_//\_\\  \____//   /_//\_\\  \____//   /____//  
 `-`  --`   `---`    `-`  --`   `---`   `-----`